Abbott's Medical Device Strategy Supports Long-Term Growth Outlook

ABT's Medical Devices segment posts 8.5% Q1 growth as Electrophysiology, Rhythm Management and Heart Failure deliver strong gains.

Abbott $ABT ABT pursues a two-pronged investment strategy within its Medical Devices segment. The company is directing resources to support the momentum in Diabetes, Structural Heart, Electrophysiology and Heart Failure, which are high-growth areas. At the same time, it continues to invest to improve the growth outlook in foundational segments like Rhythm Management and Vascular. Despite greater investor attention on traditionally fast-growing categories, management notes that the foundational businesses are also generating very impressive returns.

In the first quarter of 2026, Medical Devices’ top line grew 8.5% year over year, led by strong performance in the cardiovascular device businesses. Going deeper, Electrophysiology sales increased 13%, aided by the launch of the Volt PFA catheter, which contributed to 14% growth in the United States. Another introduction, the TactiFlex Duo catheter, helped drive mid-teens growth in Europe. The business is poised to accelerate as both these launches continue to scale.

Abbott’s Rhythm Management sales grew 13%, making the third consecutive quarter of double-digit growth and continued market outperformance. In Heart Failure, 12% growth was driven by the Heart Assist Devices portfolio for the treatment of chronic and temporary conditions.

In Diabetes Care, continuous glucose monitoring (CGM) sales reached $2 billion. However, growth was impacted by an international tender renewal delay and a difficult year-over-year comparison. Management expects CGM sales to return to double-digit growth in the second quarter.

Abbott also reported several pipeline wins during the quarter. The company completed patient enrollment in its CATALYST trial, comparing the Amulet left atrial appendage device to oral anticoagulants in patients with Atrial fibrillation (AFib). The company also started the development work for an implantable extravascular ICD product and announced positive results from a randomized controlled trial, demonstrating that the Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management.

ABT’s Peer Updates

Medtronic $MDT MDT recently received the CE mark for its Stealth AXiS surgical system, expanding access to advanced surgical technologies across Europe.The system is designed to support a wide range of clinical workflows and surgical environments and integrates planning, navigation and robotic execution into a single, modular platform. Medtronic completed the acquisition of CathWorks, the Israel-based leader in coronary digital health innovations.

Insulet PODD has enrolled the first participant in a pivotal study for its fully closed-loop (FCL) automated insulin delivery (AID) system for type 2 diabetes (T2D). The breakthrough innovation, FCL for T2D, is intended to further improve glycemic outcomes with less burden for users across diverse care settings. Insulet aims to remove barriers and expand access to AID, particularly in primary care, where roughly 70% of people with T2D are managed.

ABT Price Performance, Valuation & Estimates

Year to date, ABT shares have plunged 30.5% compared with the industry’s 23.2% decline.

Image Source: Zacks Investment Research

In terms of valuation, Abbott is trading at a forward 12-month Price/Earnings (P/E) of 15.31X, lower than its median and industry average.

Image Source: Zacks Investment Research

In the past 30 days, consensus estimates for Abbott’s earnings have trended downward.

Image Source: Zacks Investment Research

Abbott currently carries a Zacks Rank #4 (Sell).

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X $TWTR Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The essential business news, delivered fresh every morning.

Join 500,000+ readers who start their day with Quartz.

By subscribing, you agree to our Terms of Service and Privacy Policy.